EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

srGAP2 deactivates RhoA to control the duration of thrombin-mediated endothelial permeability

Alba Lopez Rioja, Ashton Faulkner, Harry Mellor iD

Vascular Biology · 01.03.2022 · 4 (1) · K1-K10

DOI: 10.1530/vb-21-0012 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Vascular Biology, erschienen am 01.03.2022. Verfasst von Alba Lopez Rioja und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Biochemistry, Biomedical Sciences Building, University of Bristol, Bristol, UK. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The endothelial barrier is a tightly regulated gateway in the transport of material between circulation and the tissues. Inflammatory mediators such as thrombin are able to open paracellular spaces in the endothelial monolayer to allow the extravasation of plasma proteins and leukocytes. Here we show that the protein SLIT-ROBO Rho GTPase-activating protein 2 (srGAP2) plays a critical role in regulating the extent of thrombin-mediated opening. We show that srGAP2 is not required for normal barrier function in resting endothelial cells, but that depletion of srGAP2 significantly increases the magnitude and duration of junctional opening in response to thrombin. We show that srGAP2 acts to switch off RhoA signaling after the contraction phase of thrombin-induced permeability, allowing respreading of cells and reformation of the barrier. srGAP2 is also required for effective restoration of the barrier after treatment with two other vasoactive agents that active RhoA – TNFα and angiotensin II. Taken together, we show that srGAP2 has a general function in controlling RhoA signaling in endothelial permeability, acting to limit the degree and duration of opening, by triggering the switch from endothelial cell contraction to respreading.

Schlagwörter

Stichwörter der Autor:innen

RhoAactin cytoskeletonendothelialpermeabilitysrGAP2

Autor:innen und Institutionen

  • School of Biochemistry, Biomedical Sciences Building, University of Bristol, Bristol, UK.

ORCID-Profile: Harry Mellor

Zitieren

APA

Lopez Rioja, A., Faulkner, A., & Mellor, H. (2022). srGAP2 deactivates RhoA to control the duration of thrombin-mediated endothelial permeability. Vascular Biology, 4(1), K1-K10. https://doi.org/10.1530/vb-21-0012

Vancouver

Lopez Rioja A, Faulkner A, Mellor H. srGAP2 deactivates RhoA to control the duration of thrombin-mediated endothelial permeability. Vascular Biology. 2022;4(1):K1-K10. doi:10.1530/vb-21-0012

BibTeX
@article{LopezRioja2022,
  author = {Lopez Rioja, Alba and Faulkner, Ashton and Mellor, Harry},
  title = {srGAP2 deactivates RhoA to control the duration of thrombin-mediated endothelial permeability},
  journal = {Vascular Biology},
  year = {2022},
  volume = {4},
  number = {1},
  pages = {K1--K10},
  doi = {10.1530/vb-21-0012}
}
Kostenlos starten →